Catalyst Pharmaceuticals Inc
NASDAQ:CPRX

Watchlist Manager
Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Watchlist
Price: 24.11 USD -0.86% Market Closed
Market Cap: 2.9B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+19%
Revenue
Forecast
+6%
Operating Income
Forecast
+4%
Net Income
Forecast
+6%

Wall Street
Price Targets

CPRX Price Targets Summary
Catalyst Pharmaceuticals Inc

Wall Street analysts forecast CPRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CPRX is 34.68 USD with a low forecast of 31.31 USD and a high forecast of 42 USD.

CPRX Lowest Forecast
Wall Street Target
31.31 USD
30% Upside
CPRX Average Forecast
Wall Street Target
34.68 USD
44% Upside
CPRX Highest Forecast
Wall Street Target
42 USD
74% Upside
Lowest
Price Target
31.31 USD
30% Upside
Average
Price Target
34.68 USD
44% Upside
Highest
Price Target
42 USD
74% Upside
Catalyst Pharmaceuticals Inc Competitors:
Price Targets
SPRY
ARS Pharmaceuticals Inc
127% Upside
CUV
Clinuvel Pharmaceuticals Ltd
151% Upside
688177
Bio-Thera Solutions Ltd
7% Upside
A
397030
AprilBio Co Ltd
115% Upside
SPRY
ARS Pharmaceuticals Inc
127% Upside
CUV
Clinuvel Pharmaceuticals Ltd
151% Upside
688177
Bio-Thera Solutions Ltd
7% Upside
A
397030
AprilBio Co Ltd
115% Upside
ZNTL
Zentalis Pharmaceuticals Inc
403% Upside
BMRN
Biomarin Pharmaceutical Inc
69% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
66% Upside
M
MAB
Mabion SA
18% Downside

Revenue
Forecast

Revenue Estimate
Catalyst Pharmaceuticals Inc

The compound annual growth rate of Catalyst Pharmaceuticals Inc's revenue for the next 3 years is 12%.

N/A
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Catalyst Pharmaceuticals Inc

The compound annual growth rate of Catalyst Pharmaceuticals Inc's operating income for the next 3 years is 19%.

N/A
Past Growth
19%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Catalyst Pharmaceuticals Inc

The compound annual growth rate of Catalyst Pharmaceuticals Inc's net income for the next 3 years is 12%.

N/A
Past Growth
12%
Estimated Growth
Estimates Accuracy
-13%
Average Miss
What are analyst estimates?

See Also

Summary
CPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CPRX stock valuation using valuation multiples.
Wall Street Estimates
CPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CPRX's stock price target?
Price Target
34.68 USD

According to Wall Street analysts, the average 1-year price target for CPRX is 34.68 USD with a low forecast of 31.31 USD and a high forecast of 42 USD.

What is Catalyst Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
12%

The compound annual growth rate of Catalyst Pharmaceuticals Inc's revenue for the next 3 years is 12%.

What is Catalyst Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
19%

The compound annual growth rate of Catalyst Pharmaceuticals Inc's operating income for the next 3 years is 19%.

What is Catalyst Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
12%

The compound annual growth rate of Catalyst Pharmaceuticals Inc's net income for the next 3 years is 12%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.